InterAx Biotech AG

InterAx Biotech AG is a Swiss biotechnology company that specializes in drug discovery, focusing primarily on G protein-coupled receptor (GPCR) targets. The company has developed a proprietary technology platform, known as Deep Signal, which integrates mathematical modeling of cellular processes, experimental methods, and machine learning. By decoding the cellular communication language and signaling pathways, this platform allows for the early-stage prediction of a drug's therapeutic effects and potential side effects. The company’s approach is designed to analyze drug chemistry and receptor structure, facilitating the design of candidates with higher efficacy, enhanced safety profiles, and a lower risk of clinical failure compared to traditional discovery methods.

This technology is significant for pharmaceutical partners and customers looking to streamline drug development, particularly in fields such as metabolic disorders, obesity, diabetes, and immuno-oncology. By providing deeper insights into disease mechanisms at the cellular signaling level before preclinical trials, InterAx aims to reduce hit-to-lead times and improve the overall success rate of drug candidates. The company, which originated as a spin-off from ETH Zurich and the Paul Scherrer Institute, actively collaborates with industry partners through various engagement models ranging from pilot studies to long-term research partnerships. Its current pipeline includes programs for weight loss and immuno-oncology.